Recap: Zogenix Q2 Earnings

Shares of Zogenix ZGNX rose in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 9.38% year over year to ($1.05), which missed the estimate of ($0.94).

Revenue of $18,789,000 higher by 1720.64% from the same period last year, which beat the estimate of $17,080,000.

Guidance

Zogenix hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 05, 2021

Time: 04:30 PM

ET Webcast URL: http://public.viavid.com/index.php?id=145894

Price Action

Company's 52-week high was at $25.88

52-week low: $15.72

Price action over last quarter: down 12.29%

Company Description

Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!